Datopotamab Deruxtecan Demonstrates Manageable Safety Profile in TNBC
Compared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.
Datopotamab deruxtecan demonstrated a manageable safety profile in treating patients with advanced or metastatic breast cancer, non–small cell lung cancer, and other tumor types, in the TROPION-PanTumor01 study (NCT03401385), explains Ian E. Krop, MD, PhD.
Krop, who is an associate chief in the Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, the clinical research director of the Breast Oncology Center, and an associate professor of medicine at Harvard Medical School, recently presented on the efficacy and safety of the TROP2-directed antibody drug conjugate (ADC) in a cohort of patients with triple-negative breast cancer at the 2021 San Antonio Breast Cancer Symposium.
In an interview with Oncology Nursing News®, Krop highlighted the promising safety profile of the drug in comparison with other ADCs.
“Only 1 of the 44 patients had to come off [the] study because of an adverse event,” he said. “If you look at the type of adverse events (AEs) people had, the most common were nausea and stomatitis. These were largely or almost predominantly low-grade events.”
“There was no drug-related pneumonitis that was seen—which is always a concern when they have drug conjugates…[and] very little hematologic toxicity, which is different than what we have seen with other with some of the other antibody-drug conjugates,” he added. “There was a very low rate of neutropenia. There was no febrile neutropenia and there [were] very low rates of diarrhea, which also was encouraging and given that this is a topoisomerase inhibitor payload, and I think it speaks to the fact that this is a very tumor selective conjugate.”
